Pamela Moore
Internal Medicine · Plano, TXNPI 1598838435
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.1% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,374 and has fallen 97.2% since, to $38 in 2023.
Across 144 payments — averaging $13.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$448
- AbbVie$212
- AstraZeneca$188
- Amarin Pharma, Inc.$179
- Merck$169
- Astellas Pharma US Inc$164
- plus $611 from 18 others
Across 292 payments — averaging $5025.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.2M
- GSK$106K
- Hikma Pharmaceuticals USA$101K
- Sanofi US Services Inc.$42K
What the payments were for
- Food & beverage$1,85694%
- Education$1176%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $448 |
| AbbVie(2 entities) | 13 | $212 |
| AstraZeneca | 13 | $188 |
| Amarin Pharma, Inc. | 20 | $179 |
| Merck | 12 | $169 |
| Astellas Pharma US Inc | 5 | $164 |
| GSK | 7 | $120 |
| Kowa Pharmaceuticals America, Inc. | 5 | $85 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $57 |
| Teva Pharmaceuticals USA, Inc. | 2 | $50 |
| Lilly USA, LLC | 3 | $39 |
| Sanofi Pasteur Inc. | 1 | $38 |
| Boehringer Ingelheim | 2 | $31 |
| Amneal Pharmaceuticals LLC | 2 | $22 |
| Coloplast | 1 | $22 |
| Sanofi | 1 | $21 |
| Medtronic | 1 | $20 |
| Pfizer | 1 | $20 |
| Eisai Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,972 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Plano
- Ayesha AmanPlano$133K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.